Christopher Wroten
Optometrist · Hammond, LANPI 1902919913
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $45,269 of the $58,589 with a category attached, or 77.3%. Alcon accounts for 66.9% of it on its own, with 24 other manufacturers making up the rest. Among optometrist clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 222 payments — averaging $263.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$39K
- Alcon Research LLC$12K
- Novartis$3K
- AbbVie$1K
- Tarsus Pharmaceuticals, Inc.$465
- Glaukos Corporation$406
- plus $2K from 19 others
What the payments were for
- Consulting fees$45,26977%
- Speaking & faculty fees$3,1805%
- Travel & lodging$2,7125%
- Food & beverage$7,40913%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 102 | $39,194 |
| Alcon Research LLC | 5 | $12,138 |
| Novartis | 12 | $2,561 |
| AbbVie(2 entities) | 30 | $1,346 |
| Tarsus Pharmaceuticals, Inc. | 10 | $465 |
| Glaukos Corporation | 4 | $406 |
| Sun Pharmaceutical Industries Inc. | 10 | $341 |
| Dompe US, Inc. | 4 | $309 |
| Johnson & Johnson Vision Care, Inc. | 6 | $238 |
| Carl Zeiss Meditec USA, Inc. | 2 | $205 |
| Biotissue Holdings Inc. | 2 | $204 |
| Mallinckrodt Hospital Products Inc. | 2 | $143 |
| Harrow Eye, LLC | 2 | $139 |
| Astellas Pharma Global Development | 2 | $125 |
| Ocular Therapeutix, Inc. | 2 | $120 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $119 |
| Aerie Pharmaceuticals, Inc. | 5 | $99 |
| Oyster Point Pharma, Inc. | 4 | $97 |
| Shire North American Group Inc | 2 | $94 |
| Coopervision Inc. | 1 | $90 |
| Bausch & Lomb Americas Inc. | 3 | $51 |
| Eyevance Pharmaceuticals LLC | 2 | $35 |
| Maculogix, Inc. | 1 | $26 |
| Kala Pharmaceuticals, Inc. | 1 | $24 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Precision 1$20,336
- DAILIES TOTAL1$18,891
- TOTAL30$12,279
- Systane$8,478
- Precision7$6,274
- Dailies Aqua Comfort Plus$5,288
- XIIDRA$2,000
- DAILIES$987
- DAILIES TOTAL1 Multifocal$700
- AIR OPTIX$679
- LUMIGAN$514
- Oxervate$248
- Photrexa Viscous and Photrexa$172
- RADIUS$144
- RESTASIS MULTIDOSE$134
- VUITY$125
- LUMERA 700$121
- Acuvue$119
- XDEMVY$118
- ACTHAR$118
How this compares
$58,589 in reported general payments places this provider in the 95th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 69 | $56,441 |
| XiidraLifitegrast | 40 | $30,021 |
| LumiganBimatoprost | 69 | $26,864 |
| VyzultaLatanoprostene Bunod | 54 | $22,772 |
| RhopressaNetarsudil Mesylate | 34 | $13,793 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $10,195 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 37 | $8,790 |
| Cyclosporine | 13 | $6,799 |
| CequaCyclosporine | 11 | $6,120 |
| Prednisolone Acetate | 139 | $4,513 |
| Lotemax SmLoteprednol Etabonate | 18 | $4,408 |
| Loteprednol Etabonate | 33 | $3,840 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 24 | $2,984 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 56 | $2,411 |
| Difluprednate | 20 | $2,107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $1,346 | $83,306138 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $51 | $52,79394 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $99 | $23,98856 claims |
| AlconSimbrinza | $39,194 | $8,79037 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $119 | $8,24851 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $341 | $6,12011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 500 optometrist providers in Louisiana.
Other optometrist in Hammond
- Pamela TheriotShreveport$207K
- Joshua DavidsonGonzales$189K
- Jeffrey WilhiteMarrero$86K
- James LamarNew Orleans$45K
- John McCallLogansport$32K
- Robert KellyMarrero$26K
- Shane FontenotJennings$23K
- Stephen LewisShreveport$17K
- Breanne McGheeNew Orleans$14K
- Robert JanotSulphur$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.